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Available online 3 February 2016Background: The modus operandi for an anti-cancer drug must allow for an efﬁcient discrimination system
between tumorigenic and non-tumorigenic cells. Targeting ER stress and mitochondrial function in cancer cells
appears to be a suitable option, as these processes are dysregulated in tumor cells. AECHL-1, a novel triterpenoid,
exhibits potent anticancer activity against an array of cancer cell lines however, its mechanism of action remains
elusive.
Methods:Molecular targets of AECHL-1 were investigated using breast adenocarcinoma cells MCF-7, MDA-MB-
231 andmammary epithelial cell lineMCF 10A in vitro and xenograft tumors in SCIDmice in vivo. Western blot-
ting, ﬂow cytometry, and immunohistochemical studies were employed to delineate the molecular pathways.
Results: AECHL-1 caused a transient elevation of ER stress proteins along with a prolonged phosphorylation of
eIF2α in breast cancer cells. This was accompanied by a simultaneous release of calcium from ER stores and sub-
sequent mitochondrial accumulation. These effects could be reversed by using ER stress inhibitors. AECHL-1
brings about mitochondria mediated, caspase independent cell death via AIF in MCF-7 cells; MDA-MB-231
succumbed to caspase dependent extrinsic pathway. Xenograft studies closely echoed our in vitro results.
AECHL-1 did not alter cellular and molecular parameters in MCF 10A.
Conclusion: These ﬁndings reveal that, AECHL-1 targets the Achilles Heel of cancer cell, namely dysfunctional ER
and mitochondria while being non toxic to normal parenchyma and can thus be further explored as a potential
chemotherapeutic intervention.
General signiﬁcance: Aggravation of ER stress by AECHL-1 uncovers a novel pathway for selective elimination of
cancer cells.








Breast cancer, despite scientiﬁc andmedical breakthroughs, remains
the reigning cause ofmortality amongwomen [1]. Many of the clinically
available chemotherapeutic compounds have encountered roadblocks
due to their toxicity towards healthy cells or due to developed resis-
tance by the cancer cells. This emphasizes the need for the development
of alternate drugs that are both selective and effective towards cancer
cells.extract-1; ER, Endoplasmic re-
ukaryotic Initiation Factor 2α;
throid-derived 2)-like factor 2;
ated Stress Response inhibitor;
TMRE, tetramethylrhodamine,
.
. This is an open access article underTriterpenoids are a group of small molecules, many of which have
proven anticancer activity in preclinical models and in clinical trials
[2]. Though the mechanism of action of apoptosis by triterpenoids
is not fully understood, some reports indicate mitochondria as
targets of apoptosis and involvement of both intrinsic as well as
extrinsic cell death pathways [3]. The extrinsic pathway is initiated
by, ligation of the death receptors and subsequent activation of
caspases-8 and caspase-10, which in turn, cleave and activate down-
stream effecter proteases, including caspases-3 and caspase-7,
causing apoptosis [4]. Mitochondria are the critical mediators of
intrinsic pathway, releasing apoptotic proteins such as cytochrome
c, aiding apoptosome formation [5]. More recently, a third pathway
that is initiated by the endoplasmic reticulum stress has been identi-
ﬁed [6].
Endoplasmic reticulum (ER) is amultifaceted organellewhose activ-
ity ranges from chaperone assisted polypeptide folding, modiﬁcation
and vesicular transport to regulation of calcium signaling. Recently ER
has also been implicated in encouraging apoptosis by activating ERthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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calcium as a secondary messenger for mitochondrial mediated apopto-
sis [7]. In tumor cell scenario, higher proliferation rates and accelerated
metabolism usually burdens cancer cells with cellular and metabolic
stress and as an adaptive response, cells generally activate ER stress
supporting survival [8,9]. However a prolonged or severe ER stress,
inﬂuenced by chemo preventive agents, tips the balance from pro-
survival to apoptosis culminating in ER stress mediated cancer cell
demise [10,11]. Since deregulation of Ca2+ homeostasis was among
the ﬁrst hallmarks of apoptosis, the signaling pathway from the ER
may be a novel therapeutic target for various cancers. Thus employing
strategies to either sensitize or persuade the cancer cells towards ER
stress may prove to be a useful tool to combat cancer cell resistance
and proliferation [12,13].
The mitochondria associated ER membrane acts as a platform for
intracellular stress cross talks and hence mitochondria have recently
emerged as intriguing targets for anticancer drugs. Themitochondria
of a cancer cell differ strikingly from that of a normal cell. The char-
acteristic features of the cancer cell mitochondria, such as the dys-
regulated Warburg effect, fatty acid synthesis and glutaminolysis,
are linked to therapeutic resistance [14]. The tumor cell mitochon-
drion is not only sluggish, which depends on aerobic glycolysis for
energy, but also exhibits a suppression of the suicidal signals which
are a pre-requisite for the cell death pathways [15]. Also the unique
ability of these cells in maintaining deﬁcient intracellular calcium
pools, keeps the mitochondria from triggering apoptotic pathways.
Targeting this dysregulated organelle along with its cross talk with
the ER will thus enable us to develop better therapeutic interven-
tions against cancer [16].
We previously reported that Ailanthus excelsa chloroform extract-1
(AECHL-1), a novel triterpenoid isolated from the root bark of Ailanthus
excelsa Roxb (Tree of Heaven), can kill human breast cancer cells more
potently. AECHL-1 has been shown to induce apoptosis in awide variety
of cancer cells in culture and suppress growth of tumor xenografts in
mouse models of breast cancer. Its activity was found to be less toxic,
more selective, and more effective in the management of tumor
progression in comparison to plant derived anti-cancer compound pac-
litaxel and metal-based compound cisplatin [17]. In addition, AECHL-1
has been shown to target tumor neo-vasculature and impair the endo-
thelial cell cytoskeleton [18]. In this study, we further investigate the
mechanism underlying tumor cell growth inhibition by AECHL-1 and
identify ER-mitochondria interaction as one of the primary targets of
its pro-apoptotic function. Ourﬁndings suggest that AECHL-1 stimulates
several apoptotic pathways in breast cancer cells; in the presence of the
normal apoptotic machinery AECHL-1 induces the classical apoptotic
pathway, however in its absence, it activates the alternate pathways
mediated by mitochondria. The concluding evidence strongly signiﬁes
the evaluation and development of AECHL-1 as a potential agent for
cancer therapy.2. Materials and methods
2.1. Cell cultures
Human breast adeno-carcinoma: MCF-7, MDA-MB-231 and normal
mammary epithelial cell line MCF 10A were obtained from ATCC
(Manassas, VA). MCF-7 cells were cultured in Dulbecco's Modiﬁed
Eagle's Medium (DMEM), supplemented with 10% FCS (Gibco) and
penicillin (100 U/ml), streptomycin (100 mg/ml) in a humidiﬁed incu-
bator at 37 °C with 5% CO2. MDA-MB-231 cells were cultured in
Leibovitz's, L-15 medium supplemented with 10% FCS and penicillin
(100 U/ml), streptomycin (100 mg/ml) in a humidiﬁed incubator at
37 °C. MCF 10A were cultured in M-171 medium supplemented with
mammary epithelial growth factors (MEGS, Life technologies) and
maintained in a humidiﬁed incubator at 37 °C with 5% CO2.2.2. Compound
AECHL-1 was isolated from the powdered root bark of A. excelsa
using silica gel column chromatography and characterized by ultra
violet (Shimadzu 1700), infra red (Perkin Elmer SpectrumRX1), nuclear
magnetic resonance (Bruker Avance I NMR Spectrometer) and mass
spectroscopy (by Jeol SX 102mass spectrometer). AECHL-1 was further
puriﬁed by HPLC on a RP C-18Phenomenex column using methanol–
water (90:10, volume for volume) as the mobile phase, and was
dissolved in DMSO as stock solution [17].
2.3. Cell viability assay
Cell viability was detected using the MTT assay as no direct interfer-
ence between AECHL-1 and MTT in a cell-free system was observed.
Brieﬂy, MCF-7, MDA-MB-231 or MCF 10A cells (4 × 103) were seeded
in a 96 well plate and allowed to grow for 24 h. The cells were then
pretreated with appropriate reagents such as the pan caspase inhibitor
Z-VAD-FMK (100 μM, Calbiochem), the antioxidants N-acetyl-cysteine
(NAC 1 mM, Sigma), Trolox (1 mM, Sigma) and glutathione (GSH
2 mM, Sigma) for 2 h, followed by exposure of the cells with 5 μM
AECHL-1 for 24 h or in case ofMCF 10A treatedwithdifferent concentra-
tions of AECHL-1 for 48 h. Cell viability was assessed byMTT (5mg/ml)
conversion as described previously [19].
2.4. Detection of apoptosis
The percent apoptotic cells were detected using the Annexin V-
FITC (BD Biosciences) binding assay. Brieﬂy cells were treated with
appropriate concentrations of AECHL-1 (5 μM for MCF-7 and MCF
10A; 15 μM for MDA-MB-231) in the presence or absence of
BAPTA-AM (1 μM, Sigma), EGTA (2 mM, Sigma), Z-VAD-FMK
(100 μM, Calbiochem), caspase 3 inhibitor Z-DEVD-FMK (20 μM, BD
Bioscience), caspase 8 inhibitor Z-IETD-FMK (20 μM, Calbiochem),
ISRIB (50 nM, Sigma) or 4-PBA (1 mM, Sigma). Cells were harvested
after 24 h (48 h for MCF 10A) and apoptosis was detected using
Annexin-V FITC along with Propidium Iodide (PI, Sigma) according
to manufacturer's instructions, on BD FACSCalibur and analyzed
using Cell Quest Pro software.
2.5. Caspase activation assay
Pan-caspase activation was studied using a commercially available
kit (Calbiochem), according to manufacturer's instructions. Brieﬂy, ap-
propriately treated cells were exposed to FITC-VAD-FMK, which binds
to active caspases and emits ﬂuorescence, which can be detected
using ﬂow cytometry (Acquisition: BD FACSCalibur, Analysis: Cell
Quest Pro software).
Caspase 3 activity was assessed using a commercially available kit
(Calbiochem), according to the manufacturer's instructions. Brieﬂy,
cells were pre-treated with caspase 8 inhibitor Z-IETD-FMK (20 μM,
Calbiochem) and caspase 3 inhibitor Z-DEVD-FMK (20 μM, BD Biosci-
ences) for 2 h followed by 15 μM AECHL-1 for 12 h. Caspase 3 activity
was detected using ﬂow cytometry (Acquisition: BD FACSCalibur,
Analysis: Cell Quest Pro software).
2.6. Changes in intracellular glutathione content, GSH
For intracellular GSH determinations in vitro, cells were either kept
untreated or treated with 5 μM (MCF-7)/15 μM AECHL-1 (MDA-MB-
231), for 24 h and processed using previously described method [20]
using Monochlorobimane (mbci, 100 μM). BD CANTO II and FACS Diva
software were used for acquisition and analysis respectively. The detec-
tion of total GSH levels in vivo was performed using a commercially
available kit (Enzo Life Sciences) and processed according to the
manufacturer's instructions.
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The variation in the mitochondrial membrane potential (Δψm) was
assessed using the cell permeant dye TMRE (40 nM, Life Technologies),
according to previously described method [21] and acquired by ﬂow
cytometry (BD FACS Calibur). Data analysis was done using the BD
Cell Quest Pro software.
2.8. Measurement of cytosolic and mitochondrial calcium
Cytosolic and mitochondrial calcium trafﬁcking were detect using
Fluo-3 AM and Rhod-2 AM respectively (2 μM, Molecular probes, Life
Technologies). Cells were processed using previously described proto-
cols [21] and acquired by ﬂow cytometry (BD FACSCalibur). Data analy-
sis was done using the BD Cell Quest Pro software.
2.9. Determination of mitochondrial mass and morphology
After treatment of MCF-7 cells with 5 μM AECHL-1, the cells were
trypsinized and resuspended in 0.5 ml of DMEM containing 100 nM
MitoTracker Green FM (Molecular Probes, Life Technologies), which
preferentially accumulates in mitochondria regardless of mitochondrial
membrane potential. After incubation for 10 min at 37 °C in dark, cells
were transferred immediately to a tube on ice for ﬂow cytometric anal-
ysis (BD FACSCalibur, USA). To assess the mitochondrial morphology,
MCF-7 cells were grown on coverslips, treated with AECHL-1 for 16 h
and stainedwithMitotracker Red (100 nM,Molecular Probes, Life Tech-
nologies) for 30 min at 37 °C in dark. The cells were washed twice with
PBS; ﬁxed using 3.7% PFA for 10 min at RT, washed and stained with
DAPI, mounted onto a glass slide and images were acquired on Zeiss
confocal microscopy at 60× magniﬁcation.
2.10. Measurement of reactive oxygen species (ROS)
In order to study the time kinetics of the ROS production,MCF-7 and
MDA-MB-231 cells (3 X 105/ml) were treated with 5 μM and 15 μM
AECHL-1 respectively for different time points (30min, 1 h, 2 h, 4 h). In-
tracellular superoxide (O2•-) was detected by dihydroethidium (DHE:
3 μM, Molecular Probes, Life Technologies) and mitochondrial superox-
ide production was studied using MitoSOX™ Red (5 μM, Molecular
Probes, Life Technologies). Cells were incubated with appropriate
probes for 30 min at 37 °C and acquired using ﬂow cytometry (BD
FACSCalibur, USA).
2.11. Calpain activity assay
Changes in the cellular calpain levels after appropriate treatments
were determined at 16 h using a commercially available calpain activity
assay kit (Abcam) and analyzed using a ﬂuorescent microplate reader
(BioTek Synergy) equipped with a 400 nm excitation ﬁlter and
505 nm emission ﬁlter according to the manufacturer's instructions.
2.12. DNA fragmentation analysis
The AECHL-1 induced DNA fragmentation was studied using a com-
mercially available TUNEL assay kit (Calbiochem) and analyzed using
ﬂow cytometry, according to the manufacturer's instructions.
2.13. Detection of protein levels by ﬂow cytometry
The levels of phospho-γH2ax, Smac /Diablo and Cytochrome c after
AECHL-1 treatment were studied using ﬂow cytometry. For Smac/
Diablo and cytochrome c, cells were treated appropriately and proc-
essed by digitonin permeabilization, according to previously described
method [22] For Phospho-γH2ax, Bax and Bcl-2, cells were trypsinized,
ﬁxed with 3.7% PFA for 10min on ice, permeabilized using 0.1% triton X100 and incubatedwith the appropriate primary antibody (1:150) in 1%
blocking buffer at 370 C for 30 min followed by washing and binding
with appropriate ﬂuorescence tagged secondary antibody (Alexa ﬂuor
488;1:300) in 1% blocking buffer at 37 °C for 30 min. Cells were then
washed twice with PBS and immediately acquired using FACSCalibur
machine. Appropriate iso-type controls were used to subtract back-
ground ﬂuorescence intensities.2.14. Immunoblotting
Cellswere subjected to the indicated treatments andwere processed
according to previously described protocols [18]. The blots were probed
using appropriate primary antibodies such as Bax, Bcl-2, pRb, total Rb,
cdk1/2, cyclin E, COX IV, Cytochrome c (1:1000, Santa Cruz Biotechnol-
ogy), pNrf2, total Nrf2, peIF2α, total eIF2α (1:1000, Abcam), total PARP,
survivin, cleaved PARP, caspase 3, PERK, BimEL (1;1000, Cell Signaling
Technology), caspase 8 (1:1000, Cell Signaling Technology) Actin
(1:10,000, ICN) and GAPDH (1:10,000, Sigma). The primary antibodies
were detected using HRP conjugated secondary antibodies (1:10,000,
Biorad).
Mitochondrial, cytosolic and nuclear fractionationsweremade using
commercially available kit (Abcam, UK). 30 μg of proteinwas probed for
AIF (1:1000, Cell Signaling Technology). Lamin A (1:1000, Cell Signaling
Technology), Actin (1:10,000, ICN) and COX IV (1:5000) were used as
nuclear cytoplasmic and mitochondrial fractionation loading controls
respectively.2.15. In vivo xenograft studies
Female SCID mice (6 to 8 weeks old; n = 6 per group) were main-
tained in accordance with the Central Animal Ethics Committee proce-
dures and guidelines (NCCS). MCF-7 cells (2 × 106cells) were
suspended in PBS and injected subcutaneously into the right ﬂank of
themice. Tumor sizewasmeasured every 3–4 days and after the tumors
reached visible proportions, the mice were injected intraperitoneally
with 5 μg AECHL-1/Kg body weight or 20 μg Paclitaxel/Kg body weight
for 10 days. Control mice were injected with PBS. Mice were observed
for further 21 days at the end of which the tumors were excised and
processed for desired experiments.2.16. Immunoﬂuorescence (IF) by Confocal Laser Scanning Microscopy
(CFLSM)
MCF 10Awere grown on coverslips and treatedwith 5 μMAECHL-
1 for 24 h. The cells were then stained with appropriate probes;
Rhod-2 AM for mitochondrial calcium, TMRE for mitochondrial
membrane potential, Mitosox Red™ and DHE for mitochondrial
and cellular ROS detection. The cells were washed twice with PBS;
ﬁxed using 3.7% PFA for 10 min at RT, washed and stained with
DAPI, mounted onto a glass slide and images were acquired on
Zeiss confocal microscopy at 60× magniﬁcation. For ﬂuorescence
imaging of in vivo tumor samples, tumors were preserved in O.C.T
compound (Fisher Healthcare, USA) and frozen at −80 °C. 5 μ
cryotome sections were obtained using a Shandon cryotome which
were air dried, ﬁxed with chilled acetone and blocked using a
blocking buffer (1% BSA, 2% FCS, 0.2% Triton–X100 and 0.05%
tween-20) for 1 h. The sections were incubated with appropriate pri-
mary antibody (peIF2α and pNrf2) for 2 h followed by secondary an-
tibody (Alexa ﬂour 488 goat anti-rabbit) for 1 h. Nuclei were counter
stained with DAPI and mounted using mounting media. Sections
were then imaged by Confocal Laser Scanning Microscopy (CFLSM)
at 60×magniﬁcation. Three random ﬁelds were imaged in 4 sections
of each tumor specimen.
Fig. 1. AECHL-1 effectuates intracellular calcium modulations in breast cancer cells. (A) MCF-7 and (B) MDA-MB-231 cells were treated with 5 μM AECHL-1 and 15 μM AECHL-1
respectively for varying time points. Cytosolic and mitochondrial calcium modulation was studied using Fluo-3 AM and Rhod-2 AM respectively by ﬂow cytometry. 2h pretreatment
with BAPTA-AM and EGTA together prevented the mitochondrial calcium surge induced by AECHL-1 in (C) MCF-7 (*p b 0.05 vs. control; #p b 0.05 vs. 5 μM AECHL-1) and (D) MDA-
MB-231 cells (***p b 0.05 vs. control; ###p b 0.05 vs. 15 μM AECHL-1). AECHL-1 induced apoptosis at 24 h was assessed after chelation of calcium using BAPTA-AM and EGTA by
Annexin V-FITC/PI staining, performed by ﬂow cytometry. (E) Dot plot representing the assay performed in MCF-7 cells. (F) Graphical representation for the same (***p b 0.001 vs.
control; #p b 0.05 vs. 5 μM AECHL-1). (G) Dot plot representing the assay performed in MDA-MB-231 cells. (H) Graphical representation for the same (*p b 0.05 vs. control; #p b 0.05
vs. 15 μM AECHL-1). Dot plots are representative of three independent experiments. FL-1H denotes Annexin V-FITC and FL-2H denotes PI staining. UR=Late apoptotic cells (Annexin
V-FITC and PI positive) and LR = Early apoptotic cells (only Annexin V-FITC positive). Graphical data represented as mean ± S.E.M of three independent experiments.
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Fig. 2. AECHL-1 does not hamper cell viability and fails tomodulate intracellular calcium transients in normalmammary cell lineMCF 10A. (A) Cell viability ofMCF 10Awas assessed after
treatment with different concentrations of AECHL-1 for 48 h byMTT assay. (B) Apoptosis detection was performed inMCF 10A cells treatedwith 5 μMAECHL-1 for 48 h using Annexin V-
FITC and PI staining by ﬂow cytometry. The data is depicted as dot plot. The horizontal (X) axis represents Annexin V-FITC and vertical (Y) axis represents PI staining. LR represents
percentage of Annexin V-FITC positive cells (early apoptotic cells), UL represents percentage of PI positive cells (necrotic cells), UR represents percentage of Annexin V-FITC and PI
positive cells (late apoptotic cells) and the percentage of live cells present in lower left quadrant are represented by red color. (C) The mitochondrial and cytosolic calcium was
detected using Rhod-2 AM and Fluo-3 AM respectively by ﬂow cytometry in MCF 10A cells treated with 5 μM AECHL-1 for varying time points. (D) Mitochondrial calcium
accumulation after 5 μM AECHL-1 treatment was detected using Rhod-2 AM in MCF 10A cells by laser scanning confocal microscopy at 24 h. Cells were ﬁxed with 3.7% PFA and the
nuclei were counterstained with DAPI. Images were acquired at 60× magniﬁcation. Results are represented as mean ± S.E.M of three independent experiments.
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All the data values are presented asmean± SEM. The in vitro data
was analyzed, using the two-sided Student's t test where as the
in vivo data was analyzed by Student's unpaired t test and tumor
growth curve was plotted using One way ANOVA followed by
Tukey's post hoc correction. P values lower than 0.05 were consid-
ered signiﬁcant.3. Results
3.1.Mitochondrial calcium overload effectuates AECHL-1 induced apoptosis
in breast cancer cells
Growing evidence demonstrates that Ca2+may play a central role in
regulation of cell death and that triggering release of intracellular Ca2+
stores and activation of the Ca2+ pathway are sufﬁcient to induce apo-
ptosis [23]. Thus we examined the cytosolic and mitochondrial calcium
levels in MCF-7 and MDA-MB-231 after treatment with AECHL-1 for
various time points. The mitochondrial calcium was labeled with
Rhod-2 AM and cytosolic calcium was detected using Fluo-3 AM by
ﬂow cytometry. AECHL-1 was found to induce a time dependent surge
in both cytosolic and mitochondrial Ca+2 levels in MCF-7 cells.
AECHL-1 lead to a transient increase in the calcium levels at 1 h followed
by a relatively long lasting calcium surge at 16 h continuing until 24 h
(Fig. 1A). A similar surge, elevating both mitochondrial and cytosolic
calcium levels above the untreated, was observed at 1 h, in MDA-MB-
231. Although the mitochondrial calcium levels were found to increasefrom initial time points till 24 h, cytosolic calcium levels were found to
decrease in later time points (Fig. 1B). A similar trend in mitochondrial
as well as cytosolic calcium ﬂux was observed in both breast cancer cell
lines, detected using confocal microscopy (Supplementary Figure S.1).
In order to conﬁrm the role of mitochondrial Ca+2 accumulation in
AECHL-1 induced apoptosis, a cell permeable Ca+2chelator BAPTA-AM
was used for scavenging intracellular calcium, while the extracellular
calcium was chelated using EGTA. 1 h Pretreatment of BAPTA- AM and
EGTAmarkedly prevented AECHL-1 induced mitochondrial calcium ac-
cumulation in MCF-7 and MDA-MB-231 cells (Fig. 1C, *p b 0.05 vs. con-
trol; #p b 0.05 vs. AECHL-1; Fig. 1D, ***p b 0.01 vs. control; ###p b 0.01 vs.
AECHL-1) respectively and subsequently suppressed apoptosis in both
MCF-7 (Fig. 1E, F, ***p b 0.001 vs. control; #p b 0.05 vs. AECHL-1) and
MDA-MB-231 (Fig. 1G, H, *p b 0.05 vs. control; #p b 0.05 vs. AECHL-1)
at 24 h. These results prove that, AECHL-1 induces breast cancer cell
apoptosis by a Ca2+-sensitive mechanism, via exclusive induction of
mitochondrial Ca2+ accumulation.
3.2. AECHL-1 was not cytotoxic to the normal mammary epithelial cell line
MCF 10A and did not induce intracellular calcium transients
In order to validate the effect of AECHL-1 on normal cell mitochon-
dria, we treated MCF 10A with various concentrations of AECHL-1 for
48 h and the cell viability was assessed by MTT assay. It was observed
that AECHL-1 was not toxic to the normal cells even at a higher concen-
tration of 100 μM (Fig. 2A; Supplementary Figure S.2). MCF 10A cells
treated with 5 μM AECHL-1 for 48 h did not show any externalization
of the phosphatidyl serine (PS) moiety as studied by Annexin V-FITC
staining, indicating an absence of apoptosis (Fig. 2B). In order to detect
Fig. 3. AECHL-1 stimulates ER stress induced apoptosis in MCF-7 and MDA-MB-231 cells. (A) AECHL-1 causes activation of ER stress proteins PERK (Protein Kinase R-like ER Kinase),
phosphorylation of eIF2α (Ser51) and induction of BimEL in a time dependent manner in MCF-7 and MDA-MB-231 cells. (B) No signiﬁcant modulations in peIF2α levels were
observed in MCF 10A cells after AECHL-1 treatment. Inhibition of ER stress using 4-PBA and ISRIB leads to reversal of the cell death in (C, D) MCF-7 (***p b 0.01 vs. control; #p b 0.05
vs. AECHL-1), (E, F) MDA-MB-231 (*p b 0.05 vs. control; #p b 0.05 vs. AECHL-1), implicating AECHL-1 induced apoptosis is mediated via ER stress as seen by Annexin V-FITC/PI
staining using ﬂow cytometry. Dot plots representative of three independent experiments. FL-1H denotes Annexin V-FITC and FL-2H denotes PI staining. UR = Late apoptotic cells
(Annexin V-FITC and PI positive) and LR = Early apoptotic cells (only Annexin V-FITC positive). The peIF2α levels induced by AECHL-1 were assessed after treatment with BAPTA-
AM+ EGTA, 4-PBA and ISRIB by western blotting in (G, H) MCF-7 (***p b 0.001 vs. control, ##p b 0.01 vs. AECHL-1, ###p b 0.001 vs. AECHL-1) and (I, J) MDA-MB-231 cells at 24 h
(*p b 0.05 vs. control, #p b 0.05 vs. AECHL-1). β-Actin was used as loading control. Graphical data represented as mean ± S.E.M of three independent experiments.
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Fig. 4. AECHL-1 induces ROS independent apoptosis in breast cancer cells. Cellular (DHE) and mitochondrial (Mitosox™ Red) superoxide levels were found to be elevated after AECHL-1
treatment in (A) MCF-7 and (B) MDA-MB-231 cells. (C) AECHL-1 did not alter the cellular and mitochondrial ROS in MCF 10A cells as seen by confocal microscopy. (D) AECHL-1
downregulated cellular antioxidants by decreasing the pNrf2 protein levels in both MCF-7 and MDA-MB-231 cells; pNrf2 levels of MCF 10A did vary after AECHL-1 treatment. (E) GSH,
a downstream target of Nrf2 was also found to be decreased in MCF-7 and MDA-MB-231 cells by AECHL-1. The marker P1 denotes cells with decreased GSH intensity. Cell death
induced by AECHL-1 was found to be independent of ROS as external supplementation of antioxidants such as NAC as well as GSH could not revert AECHL-1 induced cell death in
(F) MCF-7 as well as (G) MDA-MB-231 cells as observed by MTT assay at 24 h (*p b 0.05 vs. control, NS vs. AECHL-1; NS = non signiﬁcant). Results are represented as mean ± S.E.M
of three independent experiments.
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Fig. 5. AECHL-1 differentially regulates pro and anti- apoptotic proteins leading to mitochondrial dysfunction in MCF-7 cells. (A) AECHL-1 increased Bax: Bcl-2 ratio in vitro skewing the
balance towards apoptosis as observed using appropriate ﬂow cytometry compatible antibodies and assessed by ﬂow cytometry. The marker M1 denotes number of cells expressing
changed intensities of the corresponding protein 1 μM STS is used as a positive control. (B) The Mean ﬂuorescence intensity (MFI) was used to quantify the change in protein levels
(***p b 0.001 vs. control). (C) AECHL-1 treatment decreased mitochondrial membrane potential (Δψm) as assayed using TMRE by ﬂow cytometry in MCF-7 cells. (D) AECHL-1 does
not affect the MMP of MCF 10A cells as studied using confocal microscopy at 24 h. Cells were ﬁxed with 3.7% PFA and the nuclei were counterstained with DAPI. Images were acquired
at 60× magniﬁcation. (E) Mitochondrial cytochrome c release in a time dependent manner and (F) Smac/Diablo levels (***p b 0.001 vs. control) were quantiﬁed using the Waterhouse
Tripani method by ﬂow cytometry post AECHL-1 treatment. (G) BAPTA-AM+ EGTA pretreatment could restore back mitochondrial cytochrome c levels in cells exposed to AECHL-1 at
24 h as determined by ﬂow cytometry. The marker M1 denotes relative percentage of mitochondrial cytochrome c. (H) Release of cytochrome c into the cytosol from mitochondria
studied using cytosolic and mitochondrial lysates by western blotting at 24 h. Results are represented as mean ± S.E.M of three independent experiments.
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Fig. 6. AECHL-1 induces caspase independent programmed cell death inMCF-7 cells. (A) MCF-7 cells were treatedwith different concentrations of AECHL-1 (2.5 μM, 5 μM and 10 μM) for
12 h and caspase activation was assayed by ﬂow cytometry (B) Cell viability after 5 μMAECHL-1 treatment in presence of pan caspase inhibitor Z-VAD-FMK assessed using MTT Assay at
24 h (***p b 0.001 vs. control; NS vs. 5 μMAECHL-1; NS= non signiﬁcant). (C) DNA damage was observed after 5 μMAECHL-1 treatment by TUNEL assay in a time dependent manner by
ﬂow cytometry. (D) pH2AX levels were estimated after AECHL-1 treatment by ﬂow cytometry using appropriate antibody. 1 μM STS was used as positive control (**p b 0.01 vs. control;
***p b 0.001 vs. control). (E) Total and cleaved PARP were detected after exposure of cells to AECHL-1 in the presence or absence of BAPTA-AM and EGTA by western blotting at 24 h.
(F) Calpain activation was assayed by ﬂuorimetric estimation using a ﬂuorescence enabled microplate reader (**p b 0.01 vs. control; #p b 0.05 vs. 5 μM AECHL-1). (G) Translocation of
tAIF from mitochondria to nuclear fraction was studied by western blotting. Lamin A and COX IV were used as nuclear and mitochondrial loading controls. Results are represented as
mean ± S.E.M of three independent experiments.
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treated with 5 μM AECHL-1 for varying time points (30 min, 1 h, 2 h
and 4 h) and mitochondrial and cytosolic Ca+2 levels were assessed
using Rhod-2 AM and Fluo-3 AM respectively, by ﬂow cytometry.
AECHL-1 treatment lead to a slight but insigniﬁcant increase in the in-
tracellular calcium levels at 1 h inMCF 10A and the levels were restored
till 4 h (Fig. 2C). Themitochondrial calcium accumulation inMCF 10A at
24 h was detected by Rhod-2 AM using confocal microscopy. However
no signiﬁcant deviation in mitochondrial calcium accumulation from
the untreated cells was observed, even at 24 h (Fig. 2D).
3.3. AECHL-1 mediated ER stress induced apoptosis in breast cancer cells
Endoplasmic Reticulum (ER) is a major source of intracellular calci-
um. Leakage of calcium from the ER store under the inﬂuence of an ex-
ternal stressor causes unfolded protein response (UPR) and ultimately
ER stress. Mitochondria associated ER membrane facilitates this release
of calcium from the ER into themitochondria,where an enhancedmito-
chondrial calcium triggers apoptosis [6]. As AECHL-1 led to a time
dependent release of calcium from the ER, we speculated that AECHL-
1 may also provoke ER stress. Thus the breast cancer cell lines MCF-7
and MDA-MB-231 were treated with 5 μM AECHL-1 and 15 μM
AECHL-1 respectively for 30 min, 1 h, 2 h, 4 h and 8 h. It was observed
that AECHL-1 caused a transient upregulation of ER stress proteins
PERK and BimEL at about 30mins to 1 h and led to a prolonged phos-
phorylation of translation regulating protein eIF2α at Ser51 starting
from 30mins (Fig. 3A). In order to assess AECHL-1's toxicity in normal
cells, it's potential to initiate ER stress in MCF 10A was also evaluated
by examining the levels of peIF2α (Ser51) which showed no signiﬁcant
modulations in AECHL-1 treated cells at early (30mins to 8 h) as well as
later timepoints (24 h) (Fig. 3B). Induction of ER stresswas stalled using
inhibitors such as 4-PBA, which acts as a chemical chaperon and ISRIB,
which is a potent PERK inhibitor. Both the inhibitors reduced AECHL-1
induced apoptosis in MCF-7 (Fig. 3C, D; ***p b 0.01 vs. control;
#p b 0.05 vs. AECHL-1) as well as MDA-MB-231 cells (Fig. 3E, F;
*p b 0.05 vs. control; #p b 0.05 vs. AECHL-1) at 24 h. The ER stress inhib-
itors were also successful in normalizing the levels of peIF2α (Ser51)
after AECHL-1 treatment, in both the cancer cell lines at 24 h (Fig. 3G,
H, MCF-7, ***p b 0.001 vs. control, ##p b 0.01 vs. AECHL-1,
###p b 0.001 vs. AECHL-1; Fig. 3I, J, MDA-MB-231, *p b 0.05 vs. control,
#p b 0.05 vs. AECHL-1), thus conﬁrming the role of ER stress in
AECHL-1 mediated apoptosis.
3.4. AECHL-1 induced ROS independent apoptosis in breast cancer cells
Chemo preventive agents are known to trigger rapid and marked
production of superoxide; a key mediator of apoptotic signaling. Also
mitochondrial calcium dysregulation and overload are known to induce
a rise in ROS levels that may further impair calcium efﬂux [24]. Thus we
studied the effect of AECHL-1 on intracellular ROS levels using DHE and
mitochondrial superoxide levels using MitoSOX™ Red by ﬂow cytome-
try. Both intracellular and mitochondrial superoxide levels were found
to increase as early as 30mins to 1 h after AECHL-1 treatment in MCF-
7 cells (Fig. 4A) as well as MDA-MB-231 cells (Fig. 4B). AECHL-1 did
not alter intracellular and mitochondrial superoxide levels in the nor-
mal cell line MCF 10A (Fig. 4C). As the cellular ROS is usually quenched
by endogenous anti-oxidants, Nrf2 and its downstream anti-oxidant
GSH were examined after AECHL-1 treatment. The pNrf2 levels were
found to be downregulated in both cancer cell lines, However, the
pNrf2 levels of MCF 10A remained unaltered at 24 h (Fig. 4D). Glutathi-
one (GSH), the downstream target of Nrf2 was studied post AECHL-1
treatment and was found to be signiﬁcantly decreased in MCF-7
and MDA-MB-231 cells (Fig. 4E). Thus, indicating that AECHL-1
downregulates total cellular anti-oxidant machinery, preventing the
cell from extinguishing the damaging cellular oxidative stress. To over-
come this, we externally added general ROS quencher NAC andGSH, yetneither of the anti-oxidantswere able to restore the cell death caused by
AECHL-1 in MCF-7 as well as MDA-MB-231 cells (Fig. 4F, G,*p b 0.05 vs.
control; NS= non signiﬁcant vs. AECHL-1). These ﬁndings were further
conﬁrmed by using 1 mM Trolox, to quench cellular ROS. However no
signiﬁcant protection against AECHL-1 mediated apoptosis of breast
cancer cell lines was observed using Trolox (Supplementary Fig. 3A,
B). These observations suggest that enhanced ROS production was not
directly associated with nor critically required for AECHL-1-induced
apoptosis.
3.5. AECHL-1 differentially regulates pro and anti- apoptotic proteins
leading to mitochondrial dysfunction and release of mitochondrial pro-
apoptotic proteins in MCF-7 cells
The ratio of pro-apoptotic to anti-apoptotic protein family members
decides the fate of the cell [25]. An upregulation in this ratio leads to two
major execution programs, namely the activation of caspase pathway
and induction of mitochondrial dysfunction leading to apoptosis.
AECHL-1 treated cells exhibited a 0.5 fold downregulation in the levels
of Bcl-2 while the Bax levels were up regulated by 1.5 folds, increasing
the Bax/Bcl-2 ratio by 4 folds and tipping the balance towards apoptosis
(Fig. 5A, B; ***p b 0.001 vs. control). Activated Bax is reported to trans-
locate to the mitochondria were it brings about mitochondrial mem-
brane pore formation and a decrease in mitochondrial transmembrane
potential ΔψM (MMP). This alteration in MMP was detected using
TMRE and it was observed that cells treated with 5 μM AECHL-1
displayed a remarkable decrease in mitochondrial membrane potential
in a time dependent manner (Fig. 5C). No signiﬁcant changes in MMP
were seen in AECHL-1 treated MCF 10A cells at 24 h, indicating that
AECHL-1 did not affect the mitochondrial membrane potential of nor-
mal cells (Fig. 5D). Mitochondrial dysregulation induced by elevated
Ca+2 levels usually leads to ﬁssion of the normally elongated ﬁlamen-
tousmitochondria into smaller fragments and this alteredmitochondri-
al morphology is generally associated with apoptosis [26]. Thus, the
mitochondrial morphology, after 16 h of AECHL-1 treatment, was stud-
ied using Mitotracker red and it was observed that the mitochondria
were segregated into shorter ﬁlaments, thus indicating mitochondrial
ﬁssion (Supplementary Fig. 4A). As Ca+2 surge was observed at both
1 h and 16 h of AECHL-1 treatment, themitochondrialﬁssionwas quan-
tiﬁed using Mitotracker green which accumulates in the mitochondria
irrespective of the mitochondrial membrane potential. MCF-7 cells,
treated with 5 μM AECHL-1, displayed a distinct increase in mito-
chondrial ﬁssion and increase in mitochondrial mass per cell (Sup-
plementary Fig. 4B; ***p b 0.001 vs. control). Translocation of Bax
to mitochondria, along with decreased mitochondrial membrane
potential and mitochondrial membrane permeabilization, leads to
release of pro-apoptotic proteins such as cytochrome c, Smac/Diablo
etc., from the mitochondrial inter-membrane space [25]. We detect-
ed total cytochrome c as well as Smac/Diablo levels by ﬂow cytome-
try using the Waterhouse and Trapani method [22]. A marked time
dependent decrease in mitochondrial cytochrome c (Fig. 5E) and a
signiﬁcant decline in Smac/Diablo levels (Fig. 5F; ***p b 0.001 vs.
control) indicated the release of these proteins from the mitochon-
dria into the cytoplasm. Chelation of calcium using BAPTA-AM and
EGTA could prevent cytochrome c release from the mitochondria
into the cytosol and reinstate cytochrome c levels in AECHL-1 treated
MCF-7 cells (Fig. 5G, H) implying that its release is a consequence of
mitochondrial calcium increase.
3.6. AECHL-1 mediates caspase independent, AIF mediated programmed
cell death in MCF-7 cells
Despite the release of cytochrome c from themitochondria which is
a pre-requisite for caspase activation, AECHL-1 did not activate any
caspases (Fig. 6A). Pan caspase inhibitor failed to rescue AECHL-1 in-
duced apoptosis, suggesting AECHL-1 mediated cell death could be
Fig. 7.AECHL-1 induces caspase dependent apoptosis inMDA-MB-231 cells. (A) Detection of differential regulation of cell cycle regulatory proteins on exposure of MDA-MB-231 to 15 μM
AECHL-1 bywesternblotting at 24h.GAPDH is used as loading control.NS is non-speciﬁc band indicated by arrow. (B)AECHL-1 induces a concentration dependent increase inpan caspase
activity inMDA-MB-231 cells at 12 h as assessedbyﬂowcytometry. 300 ngPaclitaxel is used as positive control. (C) Presence of cleaved caspase 8 fragments (p43/41 andp18) and increase
in cleaved PARP on treatment of MDA-MB-231 with 15 μM AECHL-1 as assessed by western blotting. (D) Caspase 3 activation after 12 h of AECHL-1 treatment in presence or absence of
caspase 3 inhibitor (Z-DEVD-FMK) and caspase 8 inhibitor (Z-IETD-FMK). (E) Bar graph quantifying fold change in caspase 3 activity (***p b 0.001 vs. control; ##p b 0.01 vs. 15 μMAECHL-
1). (F) Dot plot representing effect of caspase 3 and 8 inhibitors onAECHL-1 induced apoptosis at 24 h, determined using Annexin V-FITC/PI staining. (G) Bar graph quantifying % apoptotic
cell number for the same (*p b 0.05 vs. control; #p b 0.05 vs. 15 μM AECHL-1). Results are represented as mean ± S.E.M of three independent experiments.
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icant vs. 5 μM AECHL-1). Thus we looked for the activation of the cas-
pase independent apoptotic pathway which is, mediated via the onset
of DNA damage, PARP hyper activation and activation of calpains. A
time dependent increase in DNA damage was observed after AECHL-1
treatment (Fig. 6C), conﬁrmed by an upregulation of pH2AX levels
(Fig. 6D; **p b 0.01 vs. control, ***p b 0.001 vs. control), which was
also accompanied by cleavage of the DNA repair enzyme PARP (Fig.
6E). As AECHL-1 caused an increase in themitochondrial Ca+2, its effect
on the activity of calpains was examined. It was found that after 16 h
of 5 μMAECHL-1 treatment; calpain activity was signiﬁcantly up reg-
ulated by 1.8 fold as compared to the untreated cells. This was abro-
gated by the pretreatment of cells with BAPTA-AM and EGTA
indicating the role of calcium mediated calpain activation in induc-
ing apoptosis (Fig. 6F; **p b 0.01 vs. control, #p b 0.05 vs. AECHL-1).
As expected, AECHL-1 lead to the activation of the caspase indepen-
dent programmed cell death, initiated by cleavage of AIF and translo-
cation of its truncated form to the nucleus frommitochondria at 24 h,
ultimately culminating in apoptosis (Fig. 6G). Chelation of Ca2+ lead
to a reversal of cell death through decreased PARP cleavage and re-
duced calpain activation along with inhibition of AIF localization in
the nucleus indicating that the apoptosis program was a conse-
quence of Ca2+ upregulation.
3.7. AECHL-1 mediates S/G2M arrest and caspase dependent apoptosis in
MDA MB-231
Since AECHL-1 induces caspase independent apoptosis in caspase 3
deﬁcient MCF-7 cells, the ability of AECHL-1 to induce cell death in
cell lines positive for caspase 3 was explored. The breast cancer cell
line MDA-MB-231, which as opposed to MCF-7 is mesenchymal in na-
ture, highly aggressive, and has a functional caspase 3. This cell line
was chosen for further experiments. AECHL-1 induced an S/G2M
phase cell cycle arrest along with a downregulation of the oncogenic
protein pRb and the cell cycle regulating proteins survivin, cyclin E
and cdk1/2 in MDA-MB-231 (Fig. 7A). Marked pan caspase activation
was seen after AECHL-1 treatment at 12 h (Fig. 7B). Even though a slight
decrease in cytochrome c levels were observed post AECHL-1 treatment
in MDA-MB-231 cells at 24 h, the deviation was not found to be signif-
icant (Supplementary Fig. 5A, B) and thus activation of extrinsic path-
way of apoptosis was explored. An exclusive initiation of the extrinsic
pathway of apoptosis was observed by cleavage of caspase 8 (indicated
by cleaved fragments 43/41 kDa and 18 kDa) aswell as cleavage of PARP
on AECHL-1 treatment in MDA-MB-231 cells using western blotting
(Fig. 7C). Pre-treatment of the cells with a caspase 8 and 3 inhibitor
stalled caspase 3 activity, (Fig. 7D, E; ***p b 0.001 vs. control;
##p b 0.01 vs. 15 μMAECHL-1) and protected cells from AECHL-1 medi-
ated apoptosis at 24 h. These ﬁndings, thus validate its caspase depen-
dent mode of action (Fig. 7F, G; *p b 0.05 vs. control; #p b 0.05 vs.
15 μM AECHL-1).
3.8. AECHL-1 treatment exhibited suppression of tumor volume of MCF-7
xenografts and demonstrated a mode of action similar to the in vitro
ﬁndings
MCF-7 xenograft tumors were treated with AECHL-1 (5 μg/kg body
weight of SCID mice) and paclitaxel (20 μg/kg body weight of SCID
mice) for 10 days and at the end of 21 days tumors were harvested
(Fig. 8A); untreated control group was injected with PBS. PBS control
xenografts displayed a signiﬁcant boost in tumor volumes on day 14
and 21 as compared to their volumes on day 0. Although no regression
in tumor volumes of AECHL-1 treated xenografts compared to their ini-
tial tumor volumes was observed in the complete study, a remarkable
suppression of tumor growth was noticed throughout the experiment.
A 29 ± 8% inhibition of tumor volumes of AECHL-1 treated group was
seen on day 7 compared to PBS controls on the same day. This deviationhowever, was not found to be signiﬁcant. On day 14 a notable 39 ±
4.01% divergence in the tumor volume of AECHL-1 treated and PBS
control group (day 14) was observed. By day 21, an appreciable 64 ±
10.21% suppression of the AECHL-1 treated xenografts was evidenced
relative to PBS control tumor volumes. In contrast, the paclitaxel treated
tumors displayed a signiﬁcant decrease in tumor volume only on day 7
and no signiﬁcant difference was observed on day 14 and 21 compared
to that of PBS controls (Fig. 8B, **p b 0.01, ***p b 0.001 vs. control on day
0, #p b 0.05 AECHL-1 vs. control on day 14, ###p b 0.001 AECHL-1 vs.
control on day 21, $p b 0.05 Paclitaxel vs. control on day 7; n = 6).
The AECHL-1 treated tumors displayed a decrease in tumor weight by
approximately 55% (**p b 0.01 vs. control; Fig. 8C) whereas that of
paclitaxel treated tumors was approximately 37% (*p b 0.05 vs. con-
trol; Fig. 8C). The phosphorylation of eIF2α (Ser51) was found to in-
crease signiﬁcantly after AECHL-1 treatment as shown by western
blotting and CFLSM indicating an induction of ER stress even in the
in vivo scenario as well as inhibition of protein synthesis (Fig. 8D,
E). AECHL-1 treatment differentially regulated the pro and the anti-
apoptotic proteins, signiﬁcantly up regulating the Bax: Bcl2 ratio
(Fig. 8F; *p b 0.05, **p b 0.01 vs. control) inducing apoptosis along
with an appreciable cleavage of the DNA repair enzyme PARP (Fig.
8G; *p b 0.05 vs. control). The in vivo anti-oxidant potential was
also evaluated by detecting pNrf2 levels by western blotting as well
as CFLSM and it was observed that AECHL-1 not only decreased the
levels of pNrf2 but also prevented its nuclear translocation thus
inhibiting its ROS scavenging capacity (Fig. 8H, I). Similarly the
downstream target of Nrf2 i.e., GSH levels were determined and
were found to be declined in comparison to total GSH levels exhibit-
ed by the control group (Fig. 8J; *p b 0.05 vs. control).
4. Discussion
In this report, we provide evidence for the mechanism of apopto-
sis induction by natural triterpenoid AECHL-1 against human breast
cancer cells in vitro and in vivo. Different mechanisms have been
proposed for the cytotoxic activity of natural triterpenoids in various
types of cancer, suggesting that cellular context is an important var-
iable. The anticancer [17] and anti-angiogenic [18] properties of a
novel triterpenoid AECHL-1 has been previously reported by us. It ef-
fectuated cell cycle arrest, microtubule disruption and a reduction in
the volume of xenograft tumors as well as normalized tumor vascu-
lature, hinting at the possibility of its efﬁcient therapeutic drug de-
livery. However, deciphering the molecular mechanisms targeted
by an anticancer agent is an integral step in its development, applica-
bility and future prospects. This report, for the ﬁrst time elucidates
the mode of action of AECHL-1 on breast cancer cells.
Calcium has been known as a regulator of both cell survival and cell
death depending on various cellular signals [23,26]. Apoptosis evasion
by a cancer cell is generally accomplished via decreased expression of
calcium permeable channels to prevent calcium inﬂux and an acquired
resistance to prolonged ER calcium deﬁciency, along with downregula-
tion ofmitochondrial calcium uniporter [27]. In our study, AECHL-1was
found to increase the mitochondrial calcium in breast cancer cells. An
initial calcium surge observed at 1 h in both MCF-7 and MDA-MB-231
cells probably indicates calcium release from the internal stores such
as ER as well as its inﬂux from extracellular milieu, probably via plasma
membrane permeabilization [28,29]. AECHL-1 achieves this, perhaps by
dysregulation of plasma membrane Ca2+-ATPase (PMCA's) and ER
Ca2+ pump SERCA which extrude Ca2+ from the cells [30]. The mito-
chondrial as well as cytosolic calcium concentrations were found to be
elevated in MCF-7 as compared to untreated cells for a prolonged time
point. In contrast, only the mitochondrial calcium levels were found to
rise in MDA-MB-231 along with a corresponding decrease in the cyto-
solic calcium levels, probably indicating transport of calcium directly
into the mitochondria via mitochondria associated ER membranes. Al-
terations in both intracellular as well as extracellular calcium
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EGTA nor BAPTA-AM alone could prevent cell death (data not shown).
However chelation of calcium by a combined treatment of BAPTA-AM
and EGTA, alleviated apoptosis, thus emphasizing on the signiﬁcance
of calcium in AECHL-1 induced cell death.Since, many anticancer agents are known to evoke an intracellular
calcium ﬂux which potentiates ER stress, exacerbating the already
existing ER stress in tumors, may prove to be a unique and selective
mode of speciﬁcally targeting cancer cells without harming the stress
free neighboring healthy cells [31]. The ER stress protein PERK is
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initiation factor 2 α (eIF2α) which is required for the activation of the
pro-apoptotic protein CHOP [32–34]. Transient activation of PERK
after AECHL-1 treatment lead to a much prolonged activation of
peIF2α which is a deﬁnite read out for ER stress. Many investigations
have reported an inhibition of protein translation during apoptosis,
mediated via a constitutive phosphorylation of eIF2α [35,36]. This
phenomenon could also be observed during AECHL-1 mediated cell
death in our study. BimEL, another proapoptotic protein associated
with ER stress [37], is also known to be upregulated by microtubule
targeting agents which triggers apoptosis via Drp-1 mediated mito-
chondrial fragmentation [38,39]. Similar events are noted in breast
cancer cells after AECHL-1 treatment which is also a microtubule
polymerizing agent, thus Drp-1 function may also be affected by
AECHL-1. Improving protein folding using a chemical chaperone 4-
PBA [40] and inhibiting PERK activity by ISRIB [41] abrogates
AECHL-1 mediated ER stress (by downregulating phosphorylation
of eIF2α) and apoptosis, suggesting that enhanced ER stress could
be a probable mode of cell death in the current study.
Due to its deviant nature, cancer cell mitochondria is emerging as a
promising target for a subset of anticancer agents having structures
similar to that of AECHL-1 [3]. Mitochondria are strategically located
at the ER calcium release site and in the presence of an ER stress this re-
leased calcium leads to mitochondrial fragmentation and apoptosis
[42]. Maintaining limited levels of this intracellular calcium pool is gen-
erally a mechanism employed by a cancer cell to render it resistant to
apoptosis [15]. AECHL-1 may possibly have upregulated the activity of
Mitochondrial Calcium Uniporter (MCU) along with a subsequent
downregulation of Na+/Ca2+ exchangers, causing lethal accumulation
ofmitochondrial calcium [43]. Augmentedmitochondrial dysregulation
via mitochondrial fragmentation and reduction in MMP by AECHL-1
further strengthens this notion. Although generated, ROS were not di-
rectly involved in AECHL-1 mediated cell demise. Never the less
AECHL-1 crippled the anti-oxidant machinery (Nrf2 and GSH) of the
cell [44], leaving damaging oxidative end products unquenched. Since
Nrf2 is known to regulate calcium homeostasis and mitochondrial bio-
energetics, a deregulation of these functions could be credited to the
down regulation of Nrf2 by AECHL-1 [45].
Cytochrome c is known to bind to IP3R channels on ER, thus blocking
Ca2+ dependent inhibition of its function, increasing Ca2+ release from
internal storage and thus aiding apoptosis [46]. Caspase 3 expression is
the primary target of many anticancer agents. Despite cytochrome c
release in our study, no caspase activation was observed in MCF-7
cells treated with AECHL-1. Extrinsic apoptotic pathway executed by
caspase 8 and 3, was implicated in AECHL-1 induced MDA-MB-231
(caspase 3 positive) cell death alongwith S/G2Mphase cell cycle arrest.
Due to a 47 bp deletion in exon 3 of the CASP3 gene,MCF-7 lacks caspase
3 expression which is the primary target of many anticancer agents.
Also, many breast tumors as well as the surrounding normal parenchy-
ma generally lack caspase 3 [47]. This makes it challenging for the che-
motherapeutic drugs to target such cancersmaking the tumors resistant
to apoptosis [48]. Caspase independent programmed cell death was
thus examined in MCF-7 cells treated with AECHL-1. An inhibition of
PARP cleavage by BAPTA and EGTA indicate that calcium is responsible
for AECHL-1 initiated PARP cleavage and thus, induction of DNA
damage. Calcium dependent cysteine proteases calpains, the foremostFig. 8. AECHL-1 decreases tumor xenograft volume in vivo, accompanied by production of ER s
and anti-apoptotic proteins. (A) AECHL-1 at 5 μg/kg bodyweightwas given intraperitoneally fo
as a positive control and vehicle control mice were injected with PBS (n = 6). (B) Bar graph de
control on day 0, #p b 0.05 AECHL-1 vs. control on day 14, ###p b 0.001 AECHL-1 vs. control o
represented in bar graph (**p b 0.01 vs. control; *p b 0.05 vs. control; n = 6). (D) peIF2α was
by western blotting (E). (F) Differential regulation of pro and anti-apoptotic proteins by AECH
(*p b 0.05, **p b 0.001 vs. control). (G) Changes in total and cleaved PARP levels were detecte
levels using CFLSM at 60× magniﬁcation (H) and western blotting (I). (J) Levels of Nrf2 target
as mean ± S.E.M of three independent experiments.mediators of caspase independent pathway, activate downstream pro-
apoptotic proteins such as Bid and Bax which cause mitochondrial per-
meability transition, localizing the truncated AIF into the nucleus [49,
50]. AECHL-1 treatment initiated a Ca2+ initiated, caspase independent,
cell death pathway, by activating calpains and causing a translocation of
AIF from the mitochondria into the nucleus, where it brings about
extensive chromatinolysis and ultimately cell death.
Further, AECHL-1 was found to be non toxic to the normal mamma-
ry cell line MCF 10A, as it failed to affect cellular and molecular param-
eters such as calcium transients, ER stress induction as well as
modulation of redox regulation (ROS and Nrf2 levels). Although
AECHL-1 increased the intracellular calcium in MCF 10A at 1 h, the in-
tensity was not signiﬁcant in comparison to MCF-7 and MDA-MB-231
calcium modulations. In addition to this the calcium ﬂux was restored
after 1 h and did not increase in the subsequent time points (24 h).
This defensive calcium buffering effect may be attributed to the pres-
ence of abundant calcium binding protein Calbindin-D28K in normal
cells relative to their cancer counterparts, which exhibit a down reg-
ulation of this protein. Calbindin-D28K is known to buffer and main-
tain the cellular calcium levels. Recent studies also suggest that
Calbindin-D28K inhibits the activation of ER stress and apoptosis
regulating proteins, hence protecting the normal cells [51]. These
conclusions strengthen previous ﬁndings and provide evidence
that AECHL-1 is speciﬁc to cancer cells. In vivo, AECHL-1 was much
more efﬁcacious as compared to the commercially used chemother-
apeutic agent paclitaxel. The mode of action exhibited in vivo was
similar to that observed in vitro.
In conclusion this study reports that AECHL-1 performs its anti-
cancer ability through selective targeting of ER stress pathway and
mitochondria, which are especially dysregulated in malignant cells.
AECHL-1 activates this cell death arsenal by modulating cellular cal-
cium levels, whose depletion is responsible for tumor resistance. In
the presence of intact apoptotic machinery, AECHL-1 executes the
classical apoptotic pathway, however in the absence of critical com-
ponents of the apoptotic cascade it switches over to alternate targets
such as mitochondria. This study strengthens AECHL-1's candidature
as an effective and accurate chemotherapeutic agent and strongly
suggests that cross-talk between ER and mitochondria mediated ap-
optosis can be further explored for human breast cancer therapy.Transparency document
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